CTNM
VENTE TOTALE: 5 000 titres (~81 170,50 $ US)
- Insiders
- Stengone Carmine N.
- Total bought
- —
- Total sold
- $81,170
- Last activity
- 2026-09-08
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-08-05
CTNM presents a deceptive liquidity profile: the high liquidity ratio (85) reflects an operationally dormant shell rather than genuine financial strength, as the company reports zero revenue, negative margins, and no…
The first sentence of the analysis written for CTNM on 2026-08-05 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 46.8% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 47.1% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | -32.2% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 46.3% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 45.4% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 45.4% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 45.4% | 0.0% | 0.0% | |
| Current Ratio | 27.496 | 20.693 | 23.287 | 6.410 | 18.993 | |
| Quick Ratio | 27.496 | 20.693 | 23.287 | 6.410 | 18.993 | |
| Solvency Ratio | -3.811 | -2.841 | 0.116 | -2.105 | -3.211 | |
| Cash Ratio | 7.759 | 2.200 | 2.831 | 0.738 | 1.260 | |
| Price To Earnings Ratio | -5.267 | -8.988 | 118.462 | -15.876 | -13.391 | |
| Price To Earnings Growth Ratio | -0.159 | 0.007 | -1.045 | 1.014 | 0.000 | |
| Forward Price To Earnings Growth Ratio | -0.159 | 0.007 | -1.045 | 1.014 | 0.000 | |
| Price To Earnings Diluted Ratio | -5.267 | -8.988 | 118.462 | -15.876 | -13.391 | |
| Price To Earnings Diluted Growth Ratio | -0.159 | 0.007 | -1.045 | 1.014 | 0.000 | |
| Price To Book Ratio | 1.213 | 1.912 | -5.697 | 9.855 | 6.284 | |
| Price To Sales Ratio | 0.000 | 0.000 | 7.740 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -5.700 | -11.354 | 20.439 | -19.122 | -14.641 | |
| Price To Operating Cash Flow Ratio | -5.724 | -11.532 | 20.002 | -19.234 | -14.734 | |
| Debt To Assets Ratio | 0.030 | 0.029 | 1.482 | 0.116 | 0.070 | |
| Debt To Equity Ratio | 0.032 | 0.032 | -2.844 | 0.149 | 0.080 | |
| Debt To Capital Ratio | 0.031 | 0.031 | 1.542 | 0.130 | 0.074 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 1.545 | 0.000 | 0.056 | |
| Financial Leverage Ratio | 1.060 | 1.075 | -1.919 | 1.289 | 1.145 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.613 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -5.677 | -3.293 | 3.528 | -2.665 | -7.149 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.387 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.004 | 1.016 | 0.979 | 1.006 | 1.006 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 111.168 | -5.428 | -17.912 | |
| Interest Coverage Ratio | 0.000 | 0.000 | -77.293 | -58.557 | -86.286 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -5.097 | -21.013 | |
| Operating Cash Flow Coverage Ratio | -6.704 | -5.248 | 0.100 | -3.440 | -5.351 | |
| Capital Expenditure Coverage Ratio | -239.446 | -63.901 | 46.737 | -170.517 | -156.345 | |
| Dividend Paid And Capex Coverage Ratio | -239.446 | -63.901 | 46.737 | -170.517 | -156.345 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.680 | -8.645 | 23.955 | -16.455 | -13.668 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-20.0% |
| Ebit Margin | 0.0% | 0.0% | ▼-9.3% |
| Ebitda Margin | 0.0% | 0.0% | ▼-9.4% |
| Operating Profit Margin | 0.0% | 0.0% | ▲6.4% |
| Pretax Profit Margin | 0.0% | 0.0% | ▼-9.3% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▼-9.1% |
| Net Profit Margin | 0.0% | 0.0% | ▼-9.1% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▼-9.1% |
| Current Ratio | 27.496 | ▲6.803 | ▲8.120 |
| Quick Ratio | 27.496 | ▲6.803 | ▲8.120 |
| Solvency Ratio | -3.811 | ▼-0.970 | ▼-1.440 |
| Cash Ratio | 7.759 | ▲5.559 | ▲4.801 |
| Price To Earnings Ratio | -5.267 | ▲3.720 | ▼-20.255 |
| Price To Earnings Growth Ratio | -0.159 | ▼-0.166 | ▼-0.122 |
| Forward Price To Earnings Growth Ratio | -0.159 | ▼-0.166 | ▼-0.122 |
| Price To Earnings Diluted Ratio | -5.267 | ▲3.720 | ▼-20.255 |
| Price To Earnings Diluted Growth Ratio | -0.159 | ▼-0.166 | ▼-0.122 |
| Price To Book Ratio | 1.213 | ▼-0.699 | ▼-1.500 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-1.548 |
| Price To Free Cash Flow Ratio | -5.700 | ▲5.654 | ▲0.375 |
| Price To Operating Cash Flow Ratio | -5.724 | ▲5.808 | ▲0.520 |
| Debt To Assets Ratio | 0.030 | ▲0.000 | ▼-0.315 |
| Debt To Equity Ratio | 0.032 | 0.000 | ▲0.542 |
| Debt To Capital Ratio | 0.031 | 0.000 | ▼-0.331 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.320 |
| Financial Leverage Ratio | 1.060 | ▼-0.015 | ▲0.530 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.123 |
| Operating Cash Flow Ratio | -5.676 | ▼-2.384 | ▼-2.625 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▼-0.077 |
| Free Cash Flow Operating Cash Flow Ratio | 1.004 | ▼-0.011 | ▲0.002 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▼-17.566 |
| Interest Coverage Ratio | 0.000 | 0.000 | ▲44.427 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲5.222 |
| Operating Cash Flow Coverage Ratio | -6.705 | ▼-1.457 | ▼-2.576 |
| Capital Expenditure Coverage Ratio | -239.446 | ▼-175.545 | ▼-122.751 |
| Dividend Paid And Capex Coverage Ratio | -239.446 | ▼-175.545 | ▼-122.751 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.680 | ▲4.965 | ▲0.019 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $316.6M | $378.8M | $387.0M | $387.0M | $387.0M | |
| Enterprise value | $249.3M | $363.1M | $564.7M | $387.3M | $387.3M | |
| EV / Sales | 0.00x | 0.00x | 11.29x | 0.00x | 0.00x | |
| EV / Op. cash flow | -4.51x | -11.05x | 29.18x | -19.25x | -14.74x | |
| EV / Free cash flow | -4.49x | -10.88x | 29.82x | -19.14x | -14.65x | |
| EV / EBITDA | -3.68x | -8.64x | 23.95x | -16.45x | -13.67x | |
| Net debt / EBITDA | 0.99x | 0.37x | 7.54x | -0.01x | -0.01x | |
| Current ratio | 27.50x | 20.69x | 23.29x | 6.41x | 18.99x | |
| Income quality | 0.92x | 0.78x | 0.85x | 0.83x | 0.91x | |
| Graham net-net | $9 | $7 | -$3 | $1 | $2 | |
| Tax burden | 100.0% | 100.0% | 98.1% | 100.0% | 100.0% | |
| Interest burden | 88.1% | 100.0% | 99.1% | 101.6% | 101.2% | |
| Working capital | $258.2M | $196.4M | $122.2M | $40.8M | $66.1M | |
| Invested capital | $266.6M | $202.9M | $123.6M | $43.0M | $66.7M | |
| Return on assets | -21.7% | -19.9% | 17.4% | -47.9% | -41.1% | |
| Operating ROA | -27.8% | -29.7% | -17.8% | -37.5% | 0.0% | |
| Return on tangible assets | -21.7% | -19.9% | 17.4% | -47.9% | -41.1% | |
| Return on equity | -23.0% | -21.3% | -33.4% | -61.8% | -47.1% | |
| Return on invested capital | -25.3% | -24.9% | -12.6% | -47.2% | -42.1% | |
| Return on capital employed | -25.5% | -25.1% | -12.9% | -52.7% | -42.9% | |
| Earnings yield | -18.9% | -11.2% | 5.9% | -6.3% | -7.5% | |
| Free cash flow yield | -17.5% | -8.8% | 4.9% | -5.2% | -6.8% | |
| Capex / Op. cash flow | -0.4% | -1.6% | 2.1% | -0.6% | -0.6% | |
| Capex / Depreciation | 71.5% | 199.2% | 212.3% | 35.9% | 51.7% | |
| Capex / Sales | 0.0% | 0.0% | 0.8% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 12.6% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 55.2% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 4.4% | 0.0% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 2562d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | -2562d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-16.4%EV / Sales n/aEV / EBITDA ▲+57.4%EV / Op. cash flow ▲+6.548Earnings yield ▼-0.078
Profitability
Return on equity ▼-0.016Return on assets ▼-0.018Return on invested capital ▼-0.004Return on capital employed ▼-0.004Operating ROA ▲+0.018Income quality ▲+0.145Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding ▼-2562.074Operating cycle n/aCash conversion cycle ▲+2562.074Capex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+6.803Net debt / EBITDA ▲+0.621Working capital ▲+61759000.000Invested capital ▲+63772000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-18.2%EV / Sales n/aEV / EBITDA ▲+73.1%EV / Op. cash flow ▲+10.238Earnings yield ▼-0.114
Profitability
Return on equity ▲+0.241Return on assets ▲+0.194Return on invested capital ▲+0.168Return on capital employed ▲+0.174Operating ROA n/aIncome quality ▲+0.017Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+8.503Net debt / EBITDA ▲+1.004Working capital ▲+192068000.000Invested capital ▲+199895000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-08-25 Contineum Therapeutics to Present at the 2026 Morgan Stanley Global Healthcare Conference SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that management is scheduled to present at the 2026 Morgan Stanley Global Healthcare Conference on Tuesday, September 15th at 5:35 p.m. ET. An audio webcast of the fireside chat can be accessed on the Investors section of.
- 2026-07-30 Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its second-quarter 2026 financial results and affirmed its key clinical development milestones. “We continue to expand our footprint for PROPEL-IPF, a global Phase 2 trial evaluating PIPE-791 for the treatment of patients.
- 2026-07-09 Are You Looking for a Top Momentum Pick? Why Contineum Therapeutics, Inc. (CTNM) is a Great Choice Does Contineum Therapeutics, Inc. (CTNM) have what it takes to be a top stock pick for momentum investors? Let''s find out.
- 2026-06-30 Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the t
- 2026-06-30 Contineum Therapeutics Publishes Discovery of Potential Best-in-Class LPAR1 Antagonist PIPE-791 in Journal of Medicinal Chemistry SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced the publication of a manuscript describing the discovery and characterization of PIPE-791 in the Journal of Medicinal Chemistry. The article, “Discovery of PIPE-791, a Potent and Brain-Penetrant Lysophosphatidic Acid R.